<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00621387</url>
  </required_header>
  <id_info>
    <org_study_id>121-853-93</org_study_id>
    <nct_id>NCT00621387</nct_id>
  </id_info>
  <brief_title>Study of Long-Term Antibiotic Treatment in Reactive Arthritis</brief_title>
  <official_title>Double-Blind, Placebo-Controlled Study of Three-Month Treatment With the Combination of Ofloxacin and Roxithromycin in Recent-Onset Reactive Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled trial of the effect of 3-month
      treatment with the combination of 200 mg ofloxacin twice daily and 150 mg roxithromycin twice
      daily on clinical course of recent-onset reactive arthritis. Patients are followed-up at
      regular intervals until 6 months. The main outcome measure is recovery from arthritis, and
      secondary outcome measures include swollen and tender joint counts, Ritchie index, joint
      pain, serum C-reactive protein level and blood erythrocyte sedimentation rate. The study will
      also address the safety and tolerability of long-term antibiotic treatment. 56 patients are
      enrolled and the enrollment of patients has been completed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 1993</start_date>
  <completion_date type="Actual">June 1998</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients recovered from arthritis</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Swollen joint count</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tender joint count</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ritchie index</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Joint pain (visual analogue scale)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum C-reactive protein level</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood erythrocyte sedimentation rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Reactive Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ofloxacin and roxithromycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ofloxacin and roxithromycin</intervention_name>
    <description>150 mg roxithromycin tablet twice daily and 200mg ofloxacin tablet twice daily for 3 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Tarivid and Surlid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo tablets identical to ofloxacin and roxithromycin twice daily for 3 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of acute reactive arthritis

          2. Preceding infection confirmed by positive culture and/or serology, or with a history
             of urethritis or gastroenteritis within the preceding 2 months

          3. Age 18 or older

        Exclusion Criteria:

          1. Allergy to quinolones or macrolides

          2. Treatment with systemic corticosteroids within 2 weeks

          3. Serum creatinine level elevated over the reference limit

          4. Alanine aminotransferase or alkaline phosphatase levels elevated over twice the
             reference limit

          5. Current or planned pregnancy, or lack of contraception

          6. Known HIV positivity

          7. Blood leukocyte count less than 4.0x109/l

          8. Blood platelet count less than 100x109/l

          9. Lack of co-operation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marjatta Leirisalo-Repo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Rheumatology, Department of Medicine, Helsinki University Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Rheumatology, Department of Medicine</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peijas Hospital</name>
      <address>
        <city>Vantaa</city>
        <zip>01400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2008</study_first_submitted>
  <study_first_submitted_qc>February 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <last_update_submitted>February 11, 2008</last_update_submitted>
  <last_update_submitted_qc>February 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2008</last_update_posted>
  <keyword>reactive arthritis</keyword>
  <keyword>antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Reactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Roxithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

